anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Expose Contradiction

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 14,162
Current window 10,621-10,650
Pages 473
Rows per page 30
Slide function: Expose Contradictionclear collectionreset all
18 30 60

Slide function

10,621-10,650 of 14,162

filter-aware
285
The slide uses a 'villain critique' approach by aggregating expert opinions to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
286
The slide uses a Q&A format to highlight the gap between the device's intended utility and real-world clinical experience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
290
The slide uses a Q&A format to highlight the perceived lack of value proposition for the OCS Lung product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
292
The slide uses highlighted text to emphasize key negative claims from a surgeon.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
295
The slide uses a direct quote from a surgeon to undermine the credibility and clinical utility of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
296
The slide uses a direct quote from an expert to undermine the value proposition of the TransMedics device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
298
The slide uses a Q&A transcript format to highlight negative expert sentiment.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
301
The slide uses direct quotes and Q&A transcripts to undermine the clinical value proposition of the TransMedics device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
302
The slide uses direct quotes to undermine the value proposition of the OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
306
The slide uses a 'villain' narrative structure to frame TransMedics as vulnerable to upcoming competition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
311
The slide highlights a competitive threat to TransMedics driven by OPO purchasing behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
312
The slide uses direct quotes from an industry expert to build a bearish case against TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
313
The slide uses a direct quote to highlight a competitive threat to TransMedics' business model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
316
Includes verbatim transcripts from a transplant surgeon regarding competitive dynamics in the liver transplant market.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
320
The slide uses direct quotes from a consultation call to highlight the competitive threat of NRP to TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
322
The slide contrasts the perceived limitations of TransMedics' technology with the functional advantages of NRP, supported by expert testimony and market evidence.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
327
The slide uses direct quotes from former employees to build a case for corporate malfeasance and product failure.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
328
The slide uses a Q&A format to present testimony, highlighting specific instances of alleged misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
329
The slide uses a Q&A transcript format to substantiate claims about corporate governance and safety oversight failures.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
330
The slide uses direct quotes from former employees and industry peers to build a case against the reliability of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
331
Includes a direct quote from a CEO of a major OPO regarding a surgeon's resignation due to safety concerns.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
332
The slide presents a Q&A format to highlight a specific technical failure mode (necrosis) attributed to the device's design.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
333
The slide uses visual evidence (images of livers and CT scans) to support the argument that machine perfusion causes lasting tissue damage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
335
The slide uses a Q&A format to highlight a specific failure in the procurement process.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
336
The slide presents a narrative of corporate deception regarding medical device performance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
337
The slide uses a Q&A format to highlight a perceived cover-up by the company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
338
The slide uses a quote to highlight a perceived lack of transparency by the company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
339
The slide presents a narrative of institutional failure and ethical concerns regarding medical device reporting.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
340
The slide uses a Q&A format to highlight a specific expert's negative experience with TransMedics equipment and corporate communication.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
341
The slide highlights a critical failure in safety protocols and regulatory compliance as perceived by an industry expert.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit